⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29957398 | 0.82 | — | — | |
| SCHEMBL2033245 | 0.82 | — | — | |
| SCHEMBL1148944 | 0.82 | — | — | |
| SCHEMBL30548405 | 0.82 | — | — | |
| SCHEMBL2033246 | 0.82 | — | — | |
| SCHEMBL18760017 | 0.80 | — | — | |
| SCHEMBL11358106 | 0.78 | KMT2A (0.42) | — | |
| SCHEMBL23565452 | 0.77 | CHRNB2 (0.37) | — | |
| SCHEMBL28632721 | 0.74 | ALDH1A1 (0.40) | — | |
| SCHEMBL30537963 | 0.72 | KDM4E (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022084738-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-04-28 | — | — | WO | disclosed |
| WO-2021045632-A1 | CANCER VACCINE | VICTORIA LINK LTD (NZ) | 2021-03-11 | — | — | WO | disclosed |
| EP-2928902-B1 | CONJUGATE COMPOUNDS | VICTORIA LINK LTD (NZ) | 2019-07-17 | — | — | EP | disclosed |
| WO-2019058289-A1 | MAIT CELL AGONISTS | VICTORIA LINK LIMITED (NZ) | 2019-03-28 | — | — | WO | disclosed |
| US-9981901-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2018-05-29 | — | — | US | disclosed |
| US-20170152206-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2017-06-01 | — | — | US | disclosed |
| US-9546149-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160168116-A1 | IRE-1alpha Inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2016-06-16 | — | — | US | disclosed |
| US-9315484-B2 | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof | The Board of Trustees—Leland Stanford Junior University (US) | 2016-04-19 | — | — | US | disclosed |
| US-9273025-B2 | — | — | 2016-03-01 | — | — | US | disclosed |
| US-20150105456-A1 | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2015-04-16 | — | — | US | disclosed |
| WO-2014088432-A1 | CONJUGATE COMPOUNDS | CALLAGHAN INNOVATION RESEARCH LIMITED (NZ) | 2014-06-12 | — | — | WO | disclosed |
| US-20140080832-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2014-03-20 | — | — | US | disclosed |
| US-20120178914-A1 | POLYPEPTIDE MODIFICATION | VYBION, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120010248-A1 | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-01-12 | — | — | US | disclosed |
| US-20110105602-A2 | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-05-05 | — | — | US | disclosed |
| US-20110065162-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2011-03-17 | — | — | US | disclosed |
| US-7858666-B2 | inositol requiring enzyme 1 (IRE-1 alpha) inhibitors such as 2-hydroxy-6-(5-(4-methylpiperazine-1-carbonyl)thiophen-2-yl)-1-naphthaldehyde, relieve protein folding stress by enhancing molecular chaperone activity and protects cells from stress induced apoptosis; autoimmune diseases; anticancer; viricides | MANNKIND CORPORATION (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090186893-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090082431-A1 | MITOCHONDRIAL ALDEHYDE DEHYDROGENASE-2 MODULATORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-26 | — | — | US | disclosed |